Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT05268237 · Recruiting

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of a sublingual (under-the-tongue) form of liraglutide in adults with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 15 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2023-04 · est. completion 2026-03

Where 1 site · Hong Kong

What this study is testing ClinicalTrials.gov NCT05268237 ↗

Description as written by the study sponsor.

This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).

Treatments tested

Liraglutide Drug

Sublingual or subcutaneous liraglutide
Placebo Drug

Sublingual placebo

Main thing measured	Incidence, nature and severity of adverse events
Sponsor	Biolingus
Conditions studied	Diabete Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05268237 ↗